Bayer's $7.25 Billion Settlement Bid Fuels a Rally Built on a Supreme Court Win

The talk around Bayer has shifted from legal dread to dividend anticipation. The German conglomerate is now seeking to put the glyphosate litigation largely behind it with a proposed $7.25 billion settlement, a move that has sent its shares surging and revived speculation about a return to meaningful shareholder payouts.

The offer follows a landmark Supreme Court ruling in late June. In the case Monsanto Co. v. Durnell, the justices sided with Bayer 7-2, ruling that federal law preempts state-level warning requirements for glyphosate. Because the Environmental Protection Agency classifies glyphosate as safe, states such as California cannot impose stricter cancer-warning labels — a decision that gutted the legal foundation for thousands of so-called "failure-to-warn" claims. The ruling gave Bayer significant leverage as it entered settlement talks for the remaining cases.

Investors have responded with a blistering buying spree. Over the past seven trading days, the stock has surged 25 percent. On Tuesday alone, the shares climbed another 5.17 percent to close at €48.23. That puts them within striking distance of the 52-week high of €49.93 — a gap of roughly 3.4 percent.

Overbought but Not Broken

The rally has pushed the relative strength index (RSI) to 79.9, deep into overbought territory. The stock now trades about 26 percent above its 50-day moving average and 31 percent above the 200-day line. With annualized volatility hovering near 60 percent, the ride has been anything but smooth. For context, peers such as BASF and Novartis barely budged half a percent on the same day.

Should investors sell immediately? Or is it worth buying Bayer?

Despite the stretched technicals, the underlying momentum remains intact. The proposed $7.25 billion settlement, if accepted by plaintiff attorneys, would resolve the vast majority of outstanding Roundup cases. Bayer has already paid out more than $10 billion to claimants globally. A formal agreement would remove the biggest overhang that has depressed the stock for years.

Dividends Back on the Table

With the legal fog lifting, market chatter has turned to Bayer's dividend policy. Analysts point to a potential payout of up to €2.50 per share — a level that would appeal to institutional investors hungry for income. The convergence of operational progress and legal clarity has created what some call "dividend fantasy" in Frankfurt.

Meanwhile, Bayer continues to push its pipeline forward without building its own AI infrastructure. A partnership with Recursion aims to accelerate drug discovery, even as rivals like Roche pour billions into proprietary AI data centers.

Bayer at a turning point? This analysis reveals what investors need to know now.

The next big question is whether the $7.25 billion offer gains enough traction among the plaintiffs. If it does, the most expensive legal saga in Bayer's history will be largely closed — and the foundation for a sustained revaluation of the equity will finally be in place.

Ad

Bayer Stock: New Analysis - 30 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69662774 |